Evidence map›Paper›PMID 42389442›Full record

ArticleExperimental and therapeutic medicine2026

Recovery from severe adriamycin-induced cardiomyopathy after prolonged intensive care in a patient with uterine leiomyosarcoma: A case report.

Kohei Tamura, Yuji Takei, Takahiro Koyanagi, Yumi Shirasu, Masahiro Taguchi, Eri Suizu, Kazuki Yamamoto, Miki Shinohara, Yoshifumi Takahashi, Akiyo Taneichi and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kohei TamuraDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Yuji TakeiDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Takahiro KoyanagiDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Yumi ShirasuDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Masahiro TaguchiDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Eri SuizuDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Kazuki YamamotoDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Miki ShinoharaDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Yoshifumi TakahashiDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Akiyo TaneichiDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Yasushi SagaDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Hiroyuki FujiwaraDepartment of Obstetrics and Gynecology, Jichi Medical University Hospital, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adriamycin (ADM) is an anthracycline widely used to treat various malignancies, including uterine leiomyosarcoma; however, cumulative dose-dependent cardiotoxicity can lead to life-threatening cardiomyopathy. Although ADM-induced cardiomyopathy has long been considered irreversible, it has been suggested that early treatment and intensive care may allow recovery in relatively mild-to-moderate heart failure (HF). By contrast, recovery of cardiac function in patients with extremely severe ADM-induced cardiomyopathy, particularly those with a left ventricular ejection fraction (LVEF) of <20% complicated by cardiogenic shock and multiorgan dysfunction requiring prolonged intensive care, is rare. The present study describes a case of severe ADM-induced cardiomyopathy following adjuvant chemotherapy for uterine leiomyosarcoma, highlighting the unexpected recovery observed after prolonged intensive care and stepwise HF management. A 40-year-old woman underwent surgical resection of a uterine leiomyosarcoma, followed by adjuvant ADM chemotherapy (cumulative dose, 450 mg/m

Indexed as

adriamycin-induced cardiomyopathyheart failureintensive careleft ventricular ejection fractionrecovery

Identifiers

PMID42389442
PMCPMC13319968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.